Preclinical Toxicity Evaluation of Erythrocyte-Encapsulated Thymidine Phosphorylase in BALB/c Mice and Beagle Dogs: An Enzyme-Replacement Therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy
| Autor: | Bridget E. Bax, Charlotte Gasson, David Coleman, Lynette D. Fairbanks, Babunilayam Gangadharan, Michelle Levene, Hugh C. Kilpatrick |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pathology
medicine.medical_specialty Erythrocytes Drug Evaluation Preclinical Pharmacology Toxicology Beagle BALB/c Blood Transfusion Autologous Mice chemistry.chemical_compound Glycogen phosphorylase Dogs Immune system Muscular Dystrophy Oculopharyngeal Mitochondrial Encephalomyopathies Toxicity Tests medicine Animals Enzyme Replacement Therapy Thymidine phosphorylase Drug Carriers Mice Inbred BALB C Thymidine Phosphorylase Ophthalmoplegia biology Intestinal Pseudo-Obstruction Enzyme replacement therapy biology.organism_classification chemistry biology.protein Antibody Erythrocyte Transfusion Thymidine |
| Zdroj: | Toxicological Sciences. 131:311-324 |
| ISSN: | 1096-0929 1096-6080 |
| DOI: | 10.1093/toxsci/kfs278 |
| Popis: | Erythrocyte-encapsulated thymidine phosphorylase (EE-TP) is currently under development as an enzyme replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), an autosomal recessive disorder caused by a deficiency of thymidine phosphorylase. The rationale for the development of EE-TP is based on the pathologically elevated metabolites (thymidine and deoxyuridine) being able to freely diffuse across the erythrocyte membrane where the encapsulated enzyme catalyses their metabolism to the normal products. The systemic toxic potential of EE-TP was assessed when administered intermittently by iv bolus injection to BALB/c mice and Beagle dogs for 4 weeks. The studies consisted of one control group receiving sham-loaded erythrocytes twice weekly and two treated groups, one dosed once every 2 weeks and the other dosed twice per week. The administration of EE-TP to BALB/c mice resulted in thrombi/emboli in the lungs and spleen enlargement. These findings were also seen in the control group, and there was no relationship to the number of doses administered. In the dog, transient clinical signs were associated with EE-TP administration, suggestive of an immune-based reaction. Specific antithymidine phosphorylase antibodies were detected in two dogs and in a greater proportion of mice treated once every 2 weeks. Nonspecific antibodies were detected in all EE-TP–treated animals. In conclusion, these studies do not reveal serious toxicities that would preclude a clinical trial of EE-TP in patients with MNGIE, but caution should be taken for infusion-related reactions that may be related to the production of nonspecific antibodies or a cell-based immune response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|